Company Filing History:
Years Active: 2013
Title: Monica Moschioni: A Pioneer in Pneumococcal Research
Introduction: Monica Moschioni, an innovative inventor based in Cose Val D'Elsa, Italy, has made significant contributions to the field of immunology through her research on pneumococcal pilus subunit RrgB. With one patent to her name, her work focuses on enhancing the efficacy of vaccines against pneumococcal diseases.
Latest Patents: Monica holds a notable patent for "Combinations of pneumococcal RrgB clades." This invention reveals that the pneumococcal pilus subunit RrgB exists in at least three clades. The serum generated against a specific clade displays activity against strains that express that clade but is ineffective against those with other clades. This discovery highlights intra-clade cross-protection while emphasizing the absence of inter-clade cross-protection. As a result, her immunogenic composition is designed to include multiple clades of RrgB to improve vaccine coverage against pilus-containing pneumococci. These clades can be incorporated into the composition either as distinct polypeptides or as a fused single polypeptide chain.
Career Highlights: Monica is currently associated with Novartis AG, an esteemed company in the pharmaceutical sector. Her research efforts have been pivotal in developing effective immunological solutions for pneumococcal infections, positioning her as a key figure in her field.
Collaborations: Throughout her career, Monica has collaborated with esteemed colleagues such as Vega Masignani and Michele Anne Barocchi. Together, they have advanced research initiatives that contribute to understanding and combating pneumococcal diseases.
Conclusion: Monica Moschioni exemplifies the spirit of innovation in the realm of medical research. Her dedication to enhancing vaccine efficacy through her patented work on pneumococcal RrgB clades marks her as a valuable asset to the scientific community and the ongoing fight against infectious diseases.